EnVivo Pharmaceuticals announced today that Deborah Dunsire, M.D. has been appointed as the new president and chief executive officer. The announcement comes just two months after Dr. Dunsire announced her retirement from Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company.
Deborah will also join the board of directors at Envivo, a company which is dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS).
“CNS diseases, including Alzheimer’s disease and schizophrenia, take a devastating toll on patients, families and the health care system…EnVivo’s late-stage lead product candidate and broad pipeline of promising clinical programs present a unique and compelling opportunity to develop new therapies with the potential to make a dramatic impact on patients’ lives. I am looking forward to working with the EnVivo team to purpose-build a biopharmaceutical company focused on transforming the CNS treatment landscape.”
Dr. Deborah Dunsire.
“Deborah’s ability to build a fully integrated biopharmaceutical company with an award-winning culture of innovation and successfully commercialize late-stage programs while developing a leading research pipeline is unparalleled…We are excited to work with Deborah.”
Stephen Knight, M.D., chairman of the EnVivo board of directors and president of Fidelity Biosciences.
Deborah brings with her more than 25 years of scientific, clinical, operational and commercial experience, in addition to proven leadership in the biological and pharmaceutical industry.
Dunsire makes quick leap from Millennium to fast-growing EnVivo (Fierce Biotech)
EnVivo Pharmaceuticals Announces Appointment of Deborah Dunsire, M.D., as President and Chief Executive Officer (Market Watch)